Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised…

19) #ESMO21 で話題になったSTAR試験の論文化。スニチニブかパゾパニブで24週無増悪なら再増悪するまで休薬する間欠的休薬戦略は、奏効しても治療を休まない従来戦略と比べてOSはほぼ同等（ITTで非劣性）、QALYも非劣性で、医療費も大幅に安い。ありかも？／Lancet Oncol htt…

RT @DrVijayPatil11: Continuous Rx verus temporary cessation 1st line TKI RCC. Overall, non-inferiority between could not be concluded. Howe…

Continuous Rx verus temporary cessation 1st line TKI RCC. Overall, non-inferiority between could not be concluded. However, there seemed to be no clinically meaningful reduction in life expectancy. https://t.co/ZeiQqikDYo

"We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma." @TheLancetOncol #MedTwitter #oncology http…